| Title | Monoclonal Antibody (mABs) Therapeutics Market is Expected to Reach $497.5 billion |
|---|
| URL | https://www.globenewswire.com/news-release/2024/04/09/2860006/0/en/Monoclonal-Antibody-mABs-Therapeutics-Market-is-Expected-to-Reach-497-5-billion-Marketsa |
|---|
| Category | Fitness Health --> Health Articles |
|---|
| Meta Keywords | Monoclonal Antibody Therapeutics Market
|
|---|
| Meta Description | Based on production method, the monoclonal antibody therapeutics market is segmented into in-vitro and in-vivo. In 2024, in-vitro segment accounted for the largest share of the monoclonal antibody therapeutics market. |
|---|
| Owner | Healthcare101 |
|---|
| Description |
|---|
| Monoclonal Antibody (mABs) Therapeutics market in terms of revenue was estimated to be worth $252.6 billion in 2024 and is poised to reach $497.5 billion by 2029, growing at a CAGR of 14.5% from 2024 to 2029 according to a latest report published by MarketsandMarkets™. The major factors driving the growth of this monoclonal antibody therapeutics market include by increasing prevalence of chronic diseases, technological advancements in antibody engineering, rising demand for targeted therapies, expanding applications in oncology, autoimmune diseases, and infectious diseases, along with growing investments in research and development, and favorable regulatory policies encouraging innovation and commercialization. |
